{"id":"https://openalex.org/W2584554595","doi":"https://doi.org/10.1158/1535-7163.mct-16-0105","title":"Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer","display_name":"Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer","publication_year":2017,"publication_date":"2017-02-01","ids":{"openalex":"https://openalex.org/W2584554595","doi":"https://doi.org/10.1158/1535-7163.mct-16-0105","mag":"2584554595","pmid":"https://pubmed.ncbi.nlm.nih.gov/28159915"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-16-0105","doi":"https://doi.org/10.1158/1535-7163.mct-16-0105","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-16-0105","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032052889","display_name":"Hatim Husain","orcid":"https://orcid.org/0000-0003-4228-0963","observed_orcids":["https://orcid.org/0000-0003-4228-0963"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hatim Husain","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055467660","display_name":"Michael D. Scur","orcid":"https://orcid.org/0000-0001-6971-2514","observed_orcids":["https://orcid.org/0000-0001-6971-2514"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Scur","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076850776","display_name":"Ayesha Murtuza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayesha Murtuza","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001300397","display_name":"Nam Q. Bui","orcid":"https://orcid.org/0000-0001-6896-4349","observed_orcids":["https://orcid.org/0000-0001-6896-4349","https://orcid.org/0000-0001-5350-7583"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nam Bui","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113779674","display_name":"Brian D. Woodward","orcid":"https://orcid.org/0000-0001-8842-3654","observed_orcids":["https://orcid.org/0000-0001-8842-3654"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Woodward","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5032052889","https://openalex.org/A5053481267"],"corresponding_institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"],"apc_list":null,"apc_paid":null,"fwci":0.9972,"has_fulltext":false,"cited_by_count":42,"citation_normalized_percentile":{"value":0.68611435,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"16","issue":"2","first_page":"265","last_page":"272"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6480000019073486},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.7770000100135803},{"id":"https://openalex.org/keywords/bypass-signaling-pathways","display_name":"bypass signaling pathways","score":0.8180000185966492},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.9010000228881836},{"id":"https://openalex.org/keywords/egfr-c797s-mutation","display_name":"C797S mutation","score":0.9860000014305115},{"id":"https://openalex.org/keywords/insulin-like-growth-factor-receptor","display_name":"insulin-like growth factor receptor","score":0.9279999732971191},{"id":"https://openalex.org/keywords/her2-amplification","display_name":"HER2 amplification","score":0.9760000109672546},{"id":"https://openalex.org/keywords/axl","display_name":"AXL","score":0.875},{"id":"https://openalex.org/keywords/building-information-modeling","display_name":"building information modeling","score":0.6809999942779541},{"id":"https://openalex.org/keywords/nf-kappab-activation","display_name":"NF-\u03baB activation","score":0.9179999828338623},{"id":"https://openalex.org/keywords/epithelial-mesenchymal-transition","display_name":"epithelial-mesenchymal transition","score":0.996999979019165},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8399999737739563},{"id":"https://openalex.org/keywords/immune-tolerance","display_name":"immune tolerance","score":0.7549999952316284},{"id":"https://openalex.org/keywords/transforming-growth-factor-beta","display_name":"TGF-beta","score":0.8370000123977661},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9610000252723694},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8560000061988831}],"concepts":[{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6838371753692627},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.6413534879684448},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5306101441383362},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48453015089035034},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46711811423301697},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.4163099229335785},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4135594964027405},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.40202319622039795},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2159019112586975},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.13078707456588745}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002471","descriptor_name":"Cell Transformation, Neoplastic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002471","descriptor_name":"Cell Transformation, Neoplastic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002471","descriptor_name":"Cell Transformation, Neoplastic","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-16-0105","doi":"https://doi.org/10.1158/1535-7163.mct-16-0105","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-16-0105","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:28159915","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28159915","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9907000064849854,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8600000143051147,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":80,"referenced_works":["https://openalex.org/W168170453","https://openalex.org/W1519936619","https://openalex.org/W1529595331","https://openalex.org/W1546552389","https://openalex.org/W1576368899","https://openalex.org/W1593770810","https://openalex.org/W1778527589","https://openalex.org/W1830835390","https://openalex.org/W1884843684","https://openalex.org/W1967394241","https://openalex.org/W1974740818","https://openalex.org/W1980497534","https://openalex.org/W1982585264","https://openalex.org/W1983774108","https://openalex.org/W1985264867","https://openalex.org/W1987283660","https://openalex.org/W1995653433","https://openalex.org/W1998971866","https://openalex.org/W2004691500","https://openalex.org/W2022406746","https://openalex.org/W2028043263","https://openalex.org/W2029572050","https://openalex.org/W2031514510","https://openalex.org/W2032397471","https://openalex.org/W2037690883","https://openalex.org/W2040104879","https://openalex.org/W2062629045","https://openalex.org/W2075445339","https://openalex.org/W2076178766","https://openalex.org/W2078897254","https://openalex.org/W2079997250","https://openalex.org/W2081801534","https://openalex.org/W2093613683","https://openalex.org/W2094882473","https://openalex.org/W2098395191","https://openalex.org/W2098674632","https://openalex.org/W2100626226","https://openalex.org/W2101581271","https://openalex.org/W2104190624","https://openalex.org/W2111490539","https://openalex.org/W2117692326","https://openalex.org/W2118101333","https://openalex.org/W2122442582","https://openalex.org/W2123918574","https://openalex.org/W2126177831","https://openalex.org/W2128649135","https://openalex.org/W2129110050","https://openalex.org/W2129656399","https://openalex.org/W2129881382","https://openalex.org/W2131323155","https://openalex.org/W2132870547","https://openalex.org/W2141303400","https://openalex.org/W2143863753","https://openalex.org/W2143913849","https://openalex.org/W2146137201","https://openalex.org/W2149542744","https://openalex.org/W2152905269","https://openalex.org/W2155338842","https://openalex.org/W2157711272","https://openalex.org/W2159657346","https://openalex.org/W2160725767","https://openalex.org/W2165359485","https://openalex.org/W2168554121","https://openalex.org/W2171313739","https://openalex.org/W2177317049","https://openalex.org/W2235360349","https://openalex.org/W2272802268","https://openalex.org/W2315744559","https://openalex.org/W2328852893","https://openalex.org/W2337507927","https://openalex.org/W2338377057","https://openalex.org/W2339311613","https://openalex.org/W2339922740","https://openalex.org/W2344546342","https://openalex.org/W2422555518","https://openalex.org/W2497014694","https://openalex.org/W2565552453","https://openalex.org/W2601574751","https://openalex.org/W6638857693","https://openalex.org/W6704630139"],"related_works":["https://openalex.org/W1975982719","https://openalex.org/W2108586722","https://openalex.org/W3028658280","https://openalex.org/W2740314095","https://openalex.org/W3000070469","https://openalex.org/W2745035390","https://openalex.org/W2066128027","https://openalex.org/W2408603676","https://openalex.org/W2209356672","https://openalex.org/W2140021827"],"abstract_inverted_index":{"The":[0],"vast":[1],"majority":[2],"of":[3,21,26,32,52,56,66,87,100,109],"patients":[4],"with":[5,81],"metastatic":[6],"lung":[7],"cancers":[8],"who":[9],"initially":[10],"benefit":[11],"from":[12],"EGFR-targeted":[13],"therapies":[14],"eventually":[15],"develop":[16],"resistance.":[17,118],"An":[18],"increasing":[19],"understanding":[20],"the":[22,30,97,107],"number":[23],"and":[24,49,85,92,106,112],"complexity":[25],"resistance":[27],"mechanisms":[28,40],"highlights":[29],"challenge":[31],"treating":[33],"tumors":[34],"resistant":[35],"to":[36,74,116],"EGFR":[37,46,103],"inhibitors.":[38],"Resistance":[39],"include":[41],"new,":[42],"second-site":[43],"mutations":[44],"within":[45],"(e.g.,":[47],"T790M":[48],"C797S),":[50],"upregulation":[51,55],"MET":[53],"kinase,":[54],"insulin":[57],"growth":[58],"factor":[59],"receptor":[60],"(IGFR),":[61],"HER2":[62],"amplification,":[63],"increased":[64],"expression":[65,80],"AXL,":[67],"BIM":[68],"modulation,":[69],"NF-\u03baB":[70],"activation,":[71],"histologic":[72],"switch":[73],"small-cell":[75],"cancer,":[76],"epithelial-to-mesenchymal":[77],"transition,":[78],"PDL1":[79],"subsequent":[82],"immune":[83],"tolerance,":[84],"release":[86],"cytokines":[88],"such":[89],"as":[90],"TGF\u03b2":[91],"IL6.":[93],"Herein,":[94],"we":[95],"review":[96],"growing":[98],"body":[99],"knowledge":[101],"regarding":[102],"bypass":[104],"pathways,":[105],"development":[108],"new":[110],"drugs":[111],"combination":[113],"treatment":[114],"strategies":[115],"overcome":[117],"Mol":[119],"Cancer":[120],"Ther;":[121],"16(2);":[122],"265-72.":[123],"\u00a92017":[124],"AACR.":[125]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-02-10T00:00:00"}